Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

The Bleeding With Antithrombotic Therapy Study 2

ID
Name
16ek0210055h
Description
The purpose of this study is to determine the incidence and severity of bleeding complications in patients with cerebrovascular and cardiovascular diseases treated with oral antithrombotic therapy.
Trial arms
Trial start
2016-10-01
Estimated PCD
2020-03-01
Trial end
2021-03-01
Status
Completed
Treatment
Any oral antithrombotics (antiplatelets or anticoagulants)
Size
5306
Primary endpoint
ISTH major bleeding
within 2 years
Eligibility criteria
Inclusion Criteria: * Patients with cerebrovascular or cardiovascular diseases who start or continue taking oral antithrombotics (antiplatelets and/or anticoagulants) to prevent vascular events * Patients who are able to receive MRI * Provision of written informed consent either directly or by a suitable surrogate Exclusion Criteria: * MRI contraindication * Any condition that in the opinion of the responsible physician or investigator that renders the patient unsuitable for the study
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '2 Years', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 5306, 'type': 'ACTUAL'}}
Updated at
2023-11-09

1 organization

1 product

1 indication

Organization
National Cerebral and Cardiovascular Center
Product
Oral antithrombotics
Indication
Cardiovascular Diseases